AUTHORS
Cheryl AC Peretz, MD, Natalia Faraj Murad, PhD, MSc, BSc2, Andrew Koh, BA3, Vanessa E Kennedy, MD4, Elaine Tran5, Dalia Dhingra6, Shu Wang7, Saurabh Gulati8, Adam Sciambi, PhD9, Olga Sala-Torra, MD10, Lan Beppu11, Krzysztof Mrózek, MD, PhD12, Deedra Nicolet, MS13, Wendy Stock, MD14, Aaron C. Logan, MD, PhD, MPhil15, Alexander E. Perl, MD16, John Byrd, MD17, Anand Ashwin Patel, MD18, Caner Saygin, MD19, Adam Olshen, PhD20, Jerald Radich, MD21, Ann-Kathrin Eisfeld, MD22, Catherine Smith, MD23
AFFILIATIONS
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 Stanford University, Palo Alto, California, United States
5 University of California San Francisco, San Francisco, California, United States
6 Mission Bio, South San Francisco, United States
7 Mission Bio, South San Francisco, United States
8 Mission Bio, South San Francisco, United States
9 Mission Bio, South San Francisco, United States
10 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
15 University of California San Francisco, San Francisco, California, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 UPMC Hillman and University of Pittsburgh, Pittsburgh, Pennsylvania, United States
18 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
19 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
20 University of California San Francisco, San Francisco, California, United States
21 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
22 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
23 University of California San Francisco, San Francisco, California, United States
ABSTRACT
Introduction
The existence of BCR::ABL1+ AML as an entity distinct from CML in myeloid blast crisis (BC-CML) is controversial. Although it is now recognized in both the ICC and WHO classifications of AML, both contain the caveat that it is poorly characterized (Arber, 2022; Khoury, 2022). Diagnostically, distinguishing the two diseases is challenging without a documented chronic phase. But a diagnosis of BCR::ABL1+ AML as a clinical entity distinct from BC-CML has implication for therapy, prognosis, and molecular monitoring. We hypothesize that with current clinical methods, a subset of patients diagnosed with BCR::ABL1+ AML actually have myeloid BC-CML. We have previously shown the feasibility of using single cell sequencing to distinguish BCR::ABL1+ AML from CML by the observation of BCR::ABL1 as a sub-clonal mutation in AML rather than a founder mutation in leukemogenesis as in CML (Kennedy, 2026). This project applies these methods to a cohort of 10 patients clinically diagnosed as BCR::ABL1+ AML.
Methods
We performed whole exome sequencing (WES) and long read nanopore sequencing of BCR::ABL1 DNA breakpoints in diagnostic samples of bone marrow and/or peripheral blood from 10 patients diagnosed with BCR::ABL1+ AML. Using these results, we designed a targeted DNA hotspot panel incorporating disease-relevant mutations and BCR::ABL1 breakpoints for each patient. We performed high-throughput single cell (SC) DNA sequencing with simultaneous cell-surface immunophenotyping (Mission Bio Tapestri). For each patient, cells were classified by both BCR::ABL1 fusion status and cell lineage (as determined by immunophenotype). Co-mutation status for individual cells was used to reconstruct leukemia phylogeny. Patients in which BCR::ABL1 was a sub-clonal mutation were classified as AML, and patients in which BCR::ABL1 was a truncal, founder mutation were classified as potential CML. In patients in which BCR::ABL1 was a truncal mutation, we next considered BCR::ABL1 breakpoint status of individual cell types. Patients in whom BCR::ABL1 was restricted to the myeloid lineage were classified as likely AML and patients in which BCR::ABL1 was equally distributed in all cell types were classified as CML.
Results
We analyzed 29,370 single cells across 10 patients (median 2,299 cells/patient). In the majority of patients (6/10), the BCR::ABL1 arose as a branch mutation from a founding leukemic clone and was not present in all leukemic populations. In this cohort, BCR::ABL1 was present in both the principal clone and sub-clones. Further, BCR::ABL1 co-mutated with other oncogenic mutational drivers rather than being in its own separate clone. In 4/10 patients, BCR::ABL1 was identified as a founder mutation and found in all leukemic cell populations. In these patients, BCR::ABL1 was found to co-mutate with other leukemia mutations in a variety of subclones (5-11 clones). In 1 of 4 patients in which BCR::ABL1 was a truncal mutation, BCR::ABL1 fusion breakpoints were detected in the majority of blast, myeloid, and mature lymphoid cell types (range 85-93% of cells), supporting its origin in a multipotent hematopoietic progenitor and consistent with a diagnosis of unrecognized CML. Analysis of additional samples is ongoing at this time and will be shared at the time of presentation.
Conclusions
Using multiomic SC analysis, these data confirm the existence of BCR::ABL1+ AML as a distinct entity, though current standard clinical tools are inadequate to reliably diagnose this disease as distinct from BC-CML. As compared to bulk BCR::ABL1 sequencing, which cannot determine disease ontogeny, SC technology can directly determine tumor phylogeny and lineage restriction of the BCR::ABL1 fusion to distinguish BCR::ABL1 AML from BC-CML. This distinction may have significant implications for prognosis, trial eligibility, treatment strategy, and evaluation of molecular response.
These findings have potential implications for other BCR::ABL1+ leukemias; additional studies are ongoing using SC analysis to distinguish lymphoid blast crisis CML from Ph+ ALL as a mechanism to resolve discordant BCR::ABL1 and high sensitivity molecular MRD in patients diagnosed with Ph+ ALL.
DISCLOSURES
Cheryl AC Peretz, MD: No relevant conflicts of interest to declare.